Literature DB >> 21223630

Microvascular decompression may be an effective treatment for nervus intermedius neuralgia.

S J F Saers1, K S Han, J A de Ru.   

Abstract

OBJECTIVE: To report microvascular decompression as a possible effective treatment for patients with nervus intermedius neuralgia, and to contribute to the literature regarding both this syndrome and this specific form of treatment.
METHOD: Case report of a patient with intermedius neuralgia. The main complaint was severe otalgia in the area innervated by the nervus intermedius, possibly caused by neurovascular compression of the nervus intermedius by the anterior inferior cerebellar artery. Microvascular decompression was undertaken, with good results.
RESULTS: Post-operatively, the patient felt immediate and total relief of her otalgia, with normal facial nerve function and no otological morbidity. One year post-operatively, she was still free from otalgia.
CONCLUSION: Patients with nervus intermedius neuralgia who do not respond to medical treatment may benefit from microvascular decompression.

Entities:  

Mesh:

Year:  2011        PMID: 21223630     DOI: 10.1017/S0022215110002677

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Microvascular decompression of the posterior inferior cerebellar artery for intermediate nerve neuralgia.

Authors:  Humberto Kluge Schroeder; Iuri Santana Neville; Daniel Ciampi de Andrade; Guilherme Alves Lepski; Manoel Jacobsen Teixeira; Kleber Paiva Duarte
Journal:  Surg Neurol Int       Date:  2015-04-01

2.  Nervus Intermedius Neuralgia Treated with Microvascular Decompression: A Case Report and Review of the Literature.

Authors:  Takuro Inoue; Ayako Shima; Hisao Hirai; Fumio Suzuki; Masayuki Matsuda
Journal:  NMC Case Rep J       Date:  2017-06-08

3.  Case Report: Direct Visualization of the Nervus Intermedius During the Microvascular Decompression Procedure: Should We Take It Seriously?

Authors:  Rui-Zhe Zheng; Chang-Yi Zhao; Zhi-Jie Zhao; Xin-Yuan Li
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.